Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Effects of cardiac contractility modulation on autophagy and apoptosis of cardiac myocytes in rabbits with chronic heart failure.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Hao Q;Hao Q;Hao Q; Lv S; Lv S; Zhang J; Zhang J; Liu H; Liu H; Liu H
  • Source:
    PloS one [PLoS One] 2024 Dec 19; Vol. 19 (12), pp. e0306242. Date of Electronic Publication: 2024 Dec 19 (Print Publication: 2024).
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
    • Abstract:
      Competing Interests: The authors have declared that no competing interests exist.
      Background: Cardiac contractility modulation (CCM) is non-excitatory electrical stimulation for improving cardiac function. This study aimed to evaluate the effects of CCM on autophagy and apoptosis of cardiac myocytes in a rabbit model of chronic heart failure (CHF) and explore its possible mechanism.
      Methods: Thirty rabbits were randomised into the Sham, heart failure (HF) and CCM groups, and animals in all three groups were sacrificed after 16 weeks of ascending aortic constriction or sham surgery. The expression of autophagy associated protein LC3 was observed by immunofluorescence staining. With Western-blot measured the expression of Beclin1, P62, LC3B (II/I) and Bcl-2, ALDH2, Bax and Caspase-3 protein in myocardial tissue. The apoptosis rate and the apoptosis of myocardial cells was observed by flow cytometry and TUNEL method.
      Results: 1) In comparison to the Sham group, the expression of LC3 and Beclin1 was significantly increased, and the expression of p62 protein was decreased in the heart tissues of rabbits in the HF group. Compared with HF group, after CCM intervention, the expression of Beclin1 and LC3B proteins decreased, while the P62 protein increased, and the LC3B(II/I) ratio decreased (P<0.05). 2) The expression of Bcl-2, ALDH2 protein and Bcl-2 mRNA decreased compared with the Sham group (P<0.05), while the expression of Bax, Caspase-3 protein and mRNA was significantly increased (P<0.05). However, the expression of ALDH2 mRNA in the CCM group was not statistically significant. The expression of Bcl-2, ALDH2 protein and mRNA increased after CCM intervention, and the expression of Bax, Caspase-3 protein and mRNA decreased (P<0.05). 3) The apoptosis situation in the Sham group was similar to that of normal myocardium, compared with the Sham group, the number of apoptotic bodies increased, and the apoptosis percentage of cardiomyocytes increased significantly (P<0.05). After CCM intervention, the number of apoptotic bodies and the percentage of apoptosis decreased compared with the HF group (P<0.05).
      Conclusions: The intervention of CCM has been shown to enhance both myocardial systolic and diastolic function in rabbits with CHF. The mechanism may be related to the inhibition of cardiomyocyte autophagy by regulating the expression levels of Beclin1, P62, and LC3B(II/I) in cardiomyocytes, as well as the reversal of cardiomyocyte apoptosis by regulating the expression levels of Bcl-2, ALDH2, Bax, and Caspase-3 in cardiomyocytes.
      (Copyright: © 2024 Hao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Circ Res. 1999 Nov 12;85(10):940-9. (PMID: 10559141)
      Lancet. 2012 Oct 20;380(9851):1387-95. (PMID: 22932717)
      Expert Rev Med Devices. 2021 Jan;18(1):15-21. (PMID: 33287592)
      Eur J Heart Fail. 2019 Oct;21(10):1169-1186. (PMID: 31129923)
      N Engl J Med. 2019 Oct 24;381(17):1609-1620. (PMID: 31475794)
      Open Med (Wars). 2022 Feb 22;17(1):365-374. (PMID: 35799598)
      Jpn J Pharmacol. 2001 Jul;86(3):355-8. (PMID: 11488438)
      J Int Med Res. 2020 Oct;48(10):300060520962910. (PMID: 33044118)
      Free Radic Biol Med. 2005 Dec 15;39(12):1570-80. (PMID: 16298682)
      ESC Heart Fail. 2020 Dec;7(6):3531-3535. (PMID: 33274601)
      Eur J Heart Fail. 2017 Nov;19(11):1414-1423. (PMID: 28463464)
      Circulation. 2002 Sep 24;106(12 Suppl 1):I212-7. (PMID: 12354736)
      N Engl J Med. 2002 Jun 13;346(24):1845-53. (PMID: 12063368)
      Circulation. 2004 Jun 22;109(24):3050-5. (PMID: 15184287)
      Eur J Heart Fail. 2018 Apr;20(4):780-791. (PMID: 29314424)
      Eur J Heart Fail. 2017 Aug;19(8):1056-1063. (PMID: 28295869)
      J Mol Cell Cardiol. 2006 Feb;40(2):283-94. (PMID: 16403513)
      Cardiovasc Res. 2006 May 1;70(2):274-85. (PMID: 16635642)
      Cell Physiol Biochem. 2014;33(5):1389-99. (PMID: 24853498)
      Eur J Heart Fail. 2018 Oct;20(10):1457-1468. (PMID: 29806208)
      JAMA. 2003 May 28;289(20):2685-94. (PMID: 12771115)
      Eur J Heart Fail. 2018 Jun;20(6):963-972. (PMID: 29464817)
      Eur J Heart Fail. 2018 Apr;20(4):769-777. (PMID: 28949083)
      Eur J Heart Fail. 2018 Jun;20(6):1039-1051. (PMID: 29457358)
      ESC Heart Fail. 2018 Feb;5(1):172-183. (PMID: 28921886)
      N Engl J Med. 2004 May 20;350(21):2140-50. (PMID: 15152059)
    • Publication Date:
      Date Created: 20241219 Date Completed: 20241219 Latest Revision: 20250104
    • Publication Date:
      20250114
    • Accession Number:
      PMC11658494
    • Accession Number:
      10.1371/journal.pone.0306242
    • Accession Number:
      39700201